On July 30, 2021, the board of directors (the “Board”) of Lumos Pharma, Inc. promoted John McKew, currently the Chief Operating Officer and Chief Scientific Officer of the Company, to serve as President of the Company, effective August 1, 2021. Dr. McKew will continue to serve as Chief Operating and Chief Scientific Officer of the Company. Richard J. Hawkins, the Company’s Chief Executive Officer, President and Chair of the Board of Directors, will continue to serve as Chief Executive Officer and Chair of the Board of Directors following Dr. Mc Kew’s promotion. Dr. McKew, 57, has served as Chief Operating Officer since April 2020 and as Chief Scientific Officer since 2016. Prior to joining the Company, Dr. McKew was V.P. of research for aTyr Pharma from 2014 until 2016. From 2010 until 2014, Dr. McKew worked for the NIH, during which time he served as a branch chief at the National Human Genome Research Institute Home (the “NHGRI”) from 2010 until 2013, and as the acting Scientific Director of the Division of Preclinical Innovation at the National Center for Advancing Translational Sciences (“NCATS”) from 2013 until 2014.
Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing its clinical program and focused on identifying, acquiring, developing, and commercializing products and new therapies for people with rare diseases. Its pipeline is focused on the development of an orally administered small molecule, LUM-201, which is a growth hormone (GH) secretagogue, also called ibutamoren, for rare endocrine disorders that require injectable recombinant human growth hormone (rhGH). LUM-201 is a tablet formulation that is intended to be administered once daily. LUM-201 stimulates GH via the GH secretagogue receptor (GHSR1a), also known as the ghrelin receptor, and also suppresses the release of somatostatin, thus providing a differentiated mechanism of action to treat some rare endocrine disorders (involving a deficiency of GH) by increasing the amplitude of endogenous, pulsatile GH secretion. Lumos Pharma Sub, Inc. (Private Lumos) is its subsidiary.
LUMOS PHARMA, INC. 
